Comparative Pharmacology
Head-to-head clinical analysis: ADENOSCAN versus SORINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOSCAN versus SORINE.
ADENOSCAN vs SORINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is a purine nucleoside that acts as a coronary vasodilator by activating A2A adenosine receptors on vascular smooth muscle, causing hyperemia. It also slows atrioventricular (AV) nodal conduction via A1 receptor activation.
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
Intravenous administration at 140 mcg/kg/min for 6 minutes (total dose 0.84 mg/kg).
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
None Documented
None Documented
< 10 seconds (biphasic: distribution half-life < 1 second, terminal elimination half-life ~0.6-1.5 seconds). Clinically, effects are rapidly terminated due to cellular uptake and metabolism.
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion of metabolites; <3% excreted unchanged in urine. Adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with further degradation to uric acid. <2% eliminated in feces.
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Category C
Category C
Antiarrhythmic
Antiarrhythmic